Conclusions
The prospect of using platform production strategies, both upstream and downstream for the rapid production of pandemic vaccines
is becoming a reality. The major bottlenecks and time constraints imposed by current egg-based or mammalian cell culture manufacturing
strategies could be alleviated by switching to a platform microbial production process. There are a number of such systems
currently in development that in real terms will significantly reduce the vaccine's time-to-market and ultimately save lives.
ANDREW CLUTTERBUCK is the downstream purification team leader, NITIN JAIN is a downstream purification scientist, and DAVID SIMPSON is the process development manager, all at Eden Biodesign, Ltd, Liverpool, UK, +44 151 728 1750, andrew.clutterbuck@edenbiodesign.com
References
1. Jeffery K. Taubenberger JK, Morens DM. 1918 Influenza: the Mother of All Pandemics. Emerg Infect Dis. 2006 Jan;12(1)15–22
Available from: http://www.cdc.gov/eid.
2. Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/h1n1flu/images.htm.
3. Roche provides additional donation of 5.65 million packs of Tamiflu to World Health Organization. Roche Media News. 12
May 2009. Available from: http://www.roche.com/med-cor-2009-05-12-e.pdf.
4. Technical data reproduced with kind permission from iQur, Ltd. (London, UK) Available from: http://www.iqur.com/.
|
